Zydus receives final approval from the USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg

Zydus receives final approval from the USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg The company also receives tentative approval for 100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg of the same drug. Ahmedabad, March 04, 2020 Zydus Cadila has received final approval from the USFDA to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg (US RLD: Truvada ® Tablets) and tentative approval for the strengths of 100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg, of the same drug. This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in the body so the immune system can work better. This will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad. The group now has 281 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, deve lops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗